Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc

被引：0
|
作者：
机构：
来源：
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN) | 2019年 / 1021卷
关键词：
CELL LUNG-CANCER; OPEN-LABEL PHASE-3; ADVANCED MELANOMA; COST-EFFECTIVENESS; PEMBROLIZUMAB; NIVOLUMAB; CHEMOTHERAPY; IPILIMUMAB; DOCETAXEL; MULTICENTER;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：314 / 331
页数：18
相关论文
共 50 条
  • [41] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [42] PD-1/PD-L1 checkpoint in hematological malignancies
    Annibali, O.
    Crescenzi, A.
    Tomarchio, V.
    Pagano, A.
    Bianchi, A.
    Grifoni, A.
    Avvisati, G.
    LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
  • [43] Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
    Sobral, Patricia S.
    Luz, Vanessa C. C.
    Almeida, Joao M. G. C. F.
    Videira, Paula A.
    Pereira, Florbela
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [44] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [45] Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
    Zhang, Yiru
    Yao, Qigu
    Pan, Yong
    Fang, Xinru
    Xu, Haoying
    Zhao, Tingxiao
    Zhu, Guangqi
    Jiang, Tianan
    Li, Shibo
    Cao, Hongcui
    CANCERS, 2023, 15 (03)
  • [46] Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Konieczny, Magdalena
    Musielak, Bogdan
    Kocik, Justyna
    Skalniak, Lukasz
    Sala, Dominik
    Czub, Miroslawa
    Magiera-Mularz, Katarzyna
    Rodriguez, Ismael
    Myrcha, Maja
    Stec, Malgorzata
    Siedlar, Maciej
    Holak, Tad A.
    Plewka, Jacek
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11271 - 11285
  • [47] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
  • [48] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [49] Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma
    Wang, Zeping
    Zou, Xiaojing
    Wang, Haiyan
    Hao, Zhihui
    Li, Gebin
    Wang, Shuaiyu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [50] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
12345